



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

4 March 2015
EMA/10452/2015
Stakeholders and Communication Division

Agenda - EMA Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP) joint meeting

4 March 2015, 09:00hrs to 17:15hrs – meeting room: 3E

Co-Chairs: Isabelle Moulon (EMA), David Haerry (PCWP), Gonzalo Calvo (HCPWP)

4 March 2015		Action	Speaker
08:30	Registration and reimbursement arrangements		
09:00	Welcome and introduction / Health and safety information Disclosure of interests / Adoption of the agenda		I. Moulon (EMA)
1. EMA 20 th Anniversary			
09:15	1.1 Roadmap to 2020	For information	N. Wathion (EMA)
10:00	1.2 Planned activities to mark the Agency's 20 th anniversary	For information	M-A. Heine (EMA)
10:30	Coffee Break		
2. Planning and reporting			
10:45	2.1 Overview of EMA interaction with healthcare professionals during 2014	For information	I. Silva (EMA)
11:00	2.2 Patients' and healthcare professionals' feedback to EMA: survey results	For information	M. Stroucken (EMA)
11:15	2.3 Working methods for 2015: working groups, topic leaders, PCO/HCPWP information sharing	For discussion	N. Bere (EMA)
11:45	2.4 Ebola update	For information	M. Cavaleri (EMA)



4 March 2015		Action	Speaker
12:15	<i>Lunch</i>		
3. EMA/EU-wide initiatives			
13:15	3.1 Encouraging paediatric clinical research in the EU – current challenges	For discussion	B. Pelle (EMA) F. Schmidt (EC)
14:15	3.2 Feedback from Scientific Committees	For information	
14:45	<i>Coffee break</i>		
15:00	3.3 Survey to national competent authorities on stakeholder involvement	For information	M. Mavris (EMA)
15:15	3.4 PROTECT/IMI project update	For information	X. Kurz (EMA)
15:45	3.5 WEBRADR/IMI project update	For information	S. Brosch/ V. Newbould (EMA) F. Houyez (PCWP) A. Hadjipanayis (HCPWP)
4. Eu Clinical trial regulation			
16:15	4.1 EMA public consultation on application of transparency rules of EU Clinical Trial Regulation	For information	F. Sweeney (EMA)
16.45	4.2 EPF statement on “lay summary of clinical trial results”	For information	K. Immonen-Charalambous (EPF)
5. AOB			
17:15	<i>End of meeting</i>		